OncoInv operates OncoSeek®, a software-based blood test that utilizes machine learning algorithms to analyze protein tumor markers for the early detection of nine high-mortality cancers. This low-cost test calculates a Probability of Cancer score and identifies the tissue of origin, facilitating timely diagnosis and improving patient outcomes.
Funding
Funding not disclosed
Founders
Product
Problem
Early detection of high-mortality cancers is crucial for improving patient outcomes, but traditional diagnostic methods can be costly, require specialized equipment, and may not be easily accessible to all populations. This can lead to delayed diagnoses and reduced chances of survival.
Solution
OncoInv offers OncoSeek®, a software-based blood test that leverages machine learning algorithms to analyze protein tumor markers for the early detection of nine high-mortality cancers. The test calculates a Probability of Cancer score and identifies the tissue of origin, facilitating timely diagnosis. OncoSeek® utilizes existing medical infrastructure and analyzes the relationships between markers and clinical factors to reduce false positives. The test is designed to be patient-friendly, requiring only a blood sample without the need for biopsies or imaging equipment. By providing a low-cost and accessible solution, OncoSeek® aims to improve cancer detection rates and patient outcomes worldwide.
Target Audience
The primary users are medical organizations and healthcare providers who provide health services to the public, particularly in low- and middle-income countries.
Features
- Analyzes concentrations of selected protein tumor markers using a machine learning algorithm.
- Detects 9 high-mortality cancers.
- Calculates a Probability of Cancer score.
- Predicts the Tissue of Origin.
- Utilizes existing medical infrastructure for easy implementation.
- Cloud-based software processes data and is GDPR compliant.